UNSPSC 51111904: Paclitaxel

This classification denotes a taxane compound and taxane-site binding agent with the molecular formula C47H51NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P88XT4IS4D, chemically known as 12-benzoate, 9-ester with (2r,3s)-n-benzoyl-3-phenylisoserine but generally known as paclitaxel, which bears US NIH Compound Identifier 36314. European Medicines Agency schedules Paclitaxel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09583MIG.

UNSPSC 51111904 Paclitaxel is a Commodity code covering the procurement of the chemotherapy drug paclitaxel by state and local health systems, hospitals, and correctional facilities. The code captures purchases of this taxane-class cancer treatment across all formulations and delivery mechanisms — including conventional paclitaxel and albumin-bound formulations — for oncology departments, infusion centers, and institutional pharmacy operations. State and local buyers use this code to solicit paclitaxel through standing purchase orders, blanket purchase agreements, and cooperative purchasing vehicles, often bundling it with other chemotherapy agents and supportive care drugs under broader pharmaceutical procurement frameworks.

The source provided contains no recent state and local contract opportunities tagged to UNSPSC 51111904. Without posted RFPs, RFQs, ITBs, or IFBs in the recent-opportunities block, no geographic concentration, issuing-body mix, or response-date signals can be established from current activity. Procurement of paclitaxel by state and local entities typically flows through existing pharmaceutical supply agreements and group purchasing organization contracts rather than through individual competitive solicitations, which may explain the absence of visible standalone opportunities under this code.